Logo Sertox

Portal latinoamericano de toxicología

Trial transparency?

18 April, 2008
From Prof. Alfredo Rovere
Guest Authorship and Ghostwriting in Publications Related to Rofecoxib.  Case Study of Industry Documents From Rofecoxib Litigation. Joseph S. Ross, MD, MHS; Kevin P. Hill, MD, MHS; David S. Egilman, MD, MPH; Harlan M. Krumholz, MD, SM. MA. 2008;299(15):1800-1812. [ Abstract ] Context Authorship
in biomedical publication provides recognition and establishes accountability and responsibility. Recent litigation related to rofecoxib provided a unique opportunity to examine guest authorship and ghostwriting, practices that have been suspected in biomedical publication but for which there is little documentation.

See also in the same number:
Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation. JAMA. 2008;299(15):1813-1817. [ Abstract ]

Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence. DeAngelis and Fontanarosa-Editorial. JAMA 2008;299:1833-1835. [ Full text ]
Add more content here...